Dostarlimab: observed
5 studies: patients on it are followed, or it is given outside a trial. Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.
- Ablative Therapy of Oligometastatic Tumor After Response to Conventional First Line TreatmentNot yet recruitingNCT07545486Report a problem
- Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal CancerRecruitingNCT07269249Report a problem
- Detection of Circulating Therapeutic Monoclonal Antibodies in Biological Samples of Gynecological Cancer Patients.Not yet recruitingNCT06797479Report a problem
- DOstarlimab in Patients With Recurrent or dMMR/MSI-H Endometrial CancerRecruitingNCT05728814Report a problem
- EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance DatabaseCompletedNCT05934214Report a problem